Exploring biomarkers in lung cancer treatment before surgery
Official title: A Prospective Cohort Study to Explore Biomarkers for Response to Neoadjuvant Chemoimmunotherapy in Stage IB-III Non-Small Cell Lung Cancer
Run by Yonsei University · NCT06907160 · Data updated 2026-11-12
This study is testing if blood and tissue samples can help doctors figure out which patients with lung cancer will benefit from treatment before surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 19 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Yonsei University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | November 1, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2029 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT06907160 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 19 years old with histologically confirmed clinical stage II-III NSCLC and no driver mutations.
✕Probably not a fit
Patients under 19 years of age, those with serious medical conditions affecting compliance, or pregnant women may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to analyze tissue and blood-based biomarkers in patients with clinical stage II-III non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemoimmunotherapy followed by surgery. It will involve collecting clinical, pathological, and radiological data from a cohort of patients, along with plasma samples taken before and after the neoadjuvant treatment. The goal is to identify non-responders to immunotherapy at diagnosis and to predict pathological complete response using non-invasive blood tests.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for lung cancer patients, improving outcomes by identifying effective therapies early.
How similar studies have gone: Other studies have shown promise in using biomarkers for predicting treatment responses in lung cancer, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven clinical stage IB-III non-small cell lung cancer * No driver mutations (EGFR mutation and ALK alteration) * Whole body performance (ECOG) 0-1 * Those over 19 years of age * Subject who submitted Informed consent form Exclusion Criteria: * Under 19 years of age * If there is a history of causing infection or other serious medical problems that impair the patient's function and make it difficult to comply with the study protocol. * Patients for whom the investigator determines that the patient should not participate in the clinical trial because the patient is judged to be unable to comply with the clinical trial procedures and requirements (a person lacking medical capacity) * Other patients (pregnant women, etc.) determined by the clinical trial director to be unsuitable for this clinical trial.
Where it's running
-
Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea Recruiting
Study contacts
- Study coordinator: Tae Hee Hong, MD, PhD
- Email: thhongcs@yuhs.ac
- Phone: (82)10-3487-6255
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
SVF cellular mix, secretome, and knee response in osteoarthritis
This study tests the cellular composition and secretome of research-only adipose-derived SVF in adults with knee OA who are already planned to receive an autologous SVF injection as part of their care.
-
2-mm subchondral drilling vs sequential 4-mm and 2-mm drilling during CARTISTEM implantation for knee cartilage defects
This study tests whether drilling the knee with a 2-mm drill alone works as well as sequential 4-mm then 2-mm drilling when combined with CARTISTEM treatment for medial knee cartilage defects.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Difference in finger, earlobe, and forehead oxygen levels to predict outcomes in dyspnea
In adults with breathing trouble, this study tests whether differences in SpO2 readings from different body sites can predict who might have worse outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.